Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shankar Lal Rampal Dye-Chem Ltd. (SRD.NS)
Bhilwara, IN
Shankar Lal Rampal Dye-Chem Limited specializes in the wholesale distribution of a wide array of dyes, chemicals, and associated materials. The company's extensive product range features items such as sulphur dyes, fully and semi-refined paraffin wax, phosphoric acid, sodium sulphide flakes, sodium hydrosulphite, hydrogen peroxide, citric acid monohydrate, various phosphate compounds, refined glycerine, sodium tripoly phosphate, tri sodium phosphate, and sodium nitrite, in addition to other chemical and dye products. Founded in 2005, this enterprise is situated in Bhilwara, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.64% | -3.60% | -11.25% | -24.28% | -34.64% | -39.10% | -40.39% | -64.63% | -64.63% | -64.63% | -64.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Chemicals - Specialty: +4.7%+15.7% ★ Q1'26: +30.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+18.5% ★ Q1'26: +90.8% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-2.1% Q1'26: -6.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+4.2% Q1'26: +4.8% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+9.7% ★ Q1'26: +13.4% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-0.1% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.31× Q1'26: 0.94× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-10 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-09 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-05 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-04 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-03 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-02 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-01 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aditi Babel | Company Secretary & Compliance Officer | 432.0K | female |
| Dinesh Chandra Inani | Whole Time Director | — | male |
| Jagdish Chandra Inani | Whole Time Director | — | male |
| Rampal Inani | MD & Chairman | — | male |
| Susheel Kumar Inani | Chief Financial Officer & Whole Time Director | — | male |
| Vinod Kumar Inani | Whole Time Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SRD.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
